Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;8(5):219.
doi: 10.1186/ar2050.

Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role

Franco Capsoni  1 , Matteo Longhi, Roberto Weinstein
Affiliations
Review

Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role

Franco Capsoni et al. Arthritis Res Ther. 2006.

Abstract

Several recent reports have described osteonecrosis of the jaws (ONJ) associated with the use of bisphosphonates. Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences. We review the literature on this newly described complication, with particular focus on systemic and local predisposing pathologies, preventive measures suggested before and during therapy with bisphosphonates, and the most frequent clinical presentation of the oral lesions. The expert panel recommendations for the management of care of patients who develop ONJ are summarized.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preventive strategy to identify patients at risk of developing bisphosphonate-associated osteonecrosis of the jaw.
See this image and copyright information in PMC

References

    1. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child. 2005;90:494–499. doi: 10.1136/adc.2003.036590. - DOI - PMC - PubMed
    1. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18:1378–1391. - PubMed
    1. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS, American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719–3736. doi: 10.1200/JCO.2002.06.037. - DOI - PubMed
    1. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(Suppl 4):28–37. doi: 10.1634/theoncologist.9-90004-28. - DOI - PubMed
    1. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4254. doi: 10.1200/JCO.2003.99.132. - DOI - PubMed

Publication types

MeSH terms

Substances